UK-based AstraZeneca has signed an agreement with US-based Foundation Medicine to develop a new diagnostic assay for Lynparza (olaparib).
Lynparza is an orally administered poly ADP-ribose polymerase (PARP) inhibitor that leverages on tumour DNA repair pathway deficiencies to eliminate cancer cells.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Under the deal, Foundation Medicine will develop a regulatory approved product based on its quality systems regulations (QSR) compliant version of FoundationOne comprehensive genomic profiling platform.
A multiple class of genomic alterations across a range of genes involved in homologous recombination repair (HRR) will be detected by the new assay, which is based on a scientifically selected panel of genes involved in driving the HRR process.
AstraZeneca Lynparza global medicine lead Nina Mojas said: "This agreement supports the broad development programme for our first-in-class PARP inhibitor, Lynparza.
"Utilising Foundation Medicine’s leading capabilities in molecular information will help our work to assess the potential of the medicine to address unmet patient need across a number of cancers driven by DNA repair deficiencies, including and significantly beyond the BRCA mutations."
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe assay will be developed in conjunction with the clinical programme for Lynparza, as a part of a coordinated drug-diagnostic regulatory strategy.
The companion diagnostic assay will assist physicians to determine the specific patients who will be benefitted from AstraZeneca’s PARP inhibitor, Lynparza.
